|
| 36787249 | Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults. | | 2023 |
| 35962033 | Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. | Nature Reviews Immunology | 2023 |
| 37645950 | Mutational basis of serum cross-neutralization profiles elicited by infection or vaccination with SARS-CoV-2 variants. | | 2023 |
| 37872011 | Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86. | | 2023 |
| 36590900 | Network analysis uncovers the communication structure of SARS-CoV-2 spike protein identifying sites for immunogen design. | | 2023 |
| 36652339 | Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1. | | 2023 |
| 36959194 | Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. | Nat Commun | 2023 |
| 37193320 | Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate. | Lancet Reg Health West Pac | 2023 |
| 37004335 | SARS-CoV-2 variant transition dynamics are associated with vaccination rates, number of co-circulating variants, and convalescent immunity. | | 2023 |
| 36697369 | Positive-strand RNA viruses-a Keystone Symposia report. | Ann N Y Acad Sci | 2023 |
| 36629414 | A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies. | mBio | 2023 |
| 37384759 | Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials. | | 2023 |
| 37188681 | Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage. | | 2023 |
| 36747640 | Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters. | | 2023 |
| 37054986 | US National Institutes of Health Prioritization of SARS-CoV-2 Variants. | Emerg Infect Dis | 2023 |
| 36859597 | Author Correction: Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. | | 2023 |
| 35081298 | SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. | N Engl J Med | 2022 |
| 35579540 | Characterization of the SARS-CoV-2 B.1.621 (Mu) variant. | Sci Transl Med | 2022 |
| 35995954 | Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. | Nature Medicine | 2022 |
| 35551291 | Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. | Nature Medicine | 2022 |
| 36264825 | Multiple lineages of monkeypox virus detected in the United States, 2021-2022. | Science | 2022 |
| 35294883 | mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. | Cell Reports | 2022 |
| 35118469 | Structural diversity of the SARS-CoV-2 Omicron spike. | | 2022 |
| 34931200 | Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization. | medRxiv | 2021 |
| 33705729 | SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. | | 2021 |
| 34169114 | Effect of epitope variant co-delivery on the depth of CD8 TÂ cell responses induced by HIV-1 conserved mosaic vaccines. | Molecular Therapy - Methods and Clinical Development | 2021 |
| 34168071 | Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. | Science | 2021 |
| 34067878 | Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2. | Viruses | 2021 |
| 33532764 | SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. | | 2021 |
| 34108654 | SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse. | Nat Microbiol | 2021 |
| 33619277 | Epigraph hemagglutinin vaccine induces broad cross-reactive immunity against swine H3 influenza virus. | Nature Communications | 2021 |
| 33450518 | Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes. | EBioMedicine | 2021 |
| 33826819 | Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. | New England Journal of Medicine | 2021 |
| 34086838 | Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. | PLoS Pathogens | 2021 |
| 33863729 | The SARS-CoV-2 Spike variant D614G favors an open conformational state. | Science advances | 2021 |
| 33306985 | D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. | | 2021 |
| 34679128 | Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens. | PLoS Pathogens | 2021 |
| 34621054 | Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. | Nature Medicine | 2021 |
| 34850742 | Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. | Journal of Clinical Investigation | 2021 |
| 32675574 | Hitting the sweet spot: exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies. | | 2020 |
| 31584318 | T cell-based strategies for HIV-1 vaccines. | Human Vaccines and Immunotherapeutics | 2020 |
| 32340576 | Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. | Annual Review of Immunology | 2020 |
| 32209678 | Estimating the Timing of Early Simian-Human Immunodeficiency Virus Infections: a Comparison between Poisson Fitter and BEAST. | mBio | 2020 |
| 33319171 | Quantification of the Resilience and Vulnerability of HIV-1 Native Glycan Shield at Atomistic Detail. | iScience | 2020 |
| 32640600 | Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth. | Vaccines | 2020 |
| 32743581 | The SARS-CoV-2 Spike Variant D614G Favors an Open Conformational State. | | 2020 |
| 32511348 | Emergence of SARS-CoV-2 through Recombination and Strong Purifying Selection. | | 2020 |
| 31263112 | Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. | Nature Communications | 2019 |
| 31527908 | Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. | PLoS Pathogens | 2019 |
| 30817809 | Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine. | PLoS Pathogens | 2019 |